The Milan experience with adjuvant chemotherapy in premenopausal breast cancer.

[1]  Stephen E. Jones,et al.  Adjuvant Therapy of Cancer , 1990 .

[2]  G. Bonadonna,et al.  The contribution of medicine to the primary treatment of breast cancer. , 1988, Cancer research.

[3]  H. Mouridsen,et al.  Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  I. Henderson,et al.  Adjuvant systemic therapy for early breast cancer. , 1987, Current Problems in Cancer.

[5]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[6]  G. Bonadonna,et al.  The CMF program for operable breast cancer with positive axillary nodes: Updated analysis on the disease‐free interval, site of relapse and drug tolerance , 1977, Cancer.

[7]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[8]  G. Bonadonna,et al.  Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.

[9]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[10]  M. Zelen,et al.  A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. , 1985, Cancer research.

[11]  G. Bonadonna,et al.  Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.